MO2 Stock Overview
Medcolcanna Organics Inc. operates as a medical cannabis company in Colombia and Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Medcolcanna Organics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.051 |
| 52 Week Low | CA$0.0005 |
| Beta | 1.22 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -98.90% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| MO2 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -6.0% | -1.3% |
| 1Y | -98.9% | -31.5% | 4.1% |
Return vs Industry: MO2 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: MO2 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| MO2 volatility | |
|---|---|
| MO2 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 9.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MO2's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MO2's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 90 | Felipe De La Vega | https://medcolcanna.com |
Medcolcanna Organics Inc. operates as a medical cannabis company in Colombia and Switzerland. The company cultivates, produces, and distributes medicinal cannabis and cannabis derived products, including pharmaceutical, cosmetic, and bulk API products. Medcolcanna Organics Inc. is based in Calgary, Canada.
Medcolcanna Organics Inc. Fundamentals Summary
| MO2 fundamental statistics | |
|---|---|
| Market cap | €634.35k |
| Earnings (TTM) | -€4.75m |
| Revenue (TTM) | €236.65k |
2.7x
P/S Ratio-0.1x
P/E RatioIs MO2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MO2 income statement (TTM) | |
|---|---|
| Revenue | CA$316.61k |
| Cost of Revenue | CA$1.95m |
| Gross Profit | -CA$1.63m |
| Other Expenses | CA$4.73m |
| Earnings | -CA$6.35m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.037 |
| Gross Margin | -514.55% |
| Net Profit Margin | -2,007.02% |
| Debt/Equity Ratio | -102.1% |
How did MO2 perform over the long term?
See historical performance and comparison